We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Stay up to date on the topics that matter to you

A picture of Laura Elizabeth Lansdowne

Laura Elizabeth Lansdowne profile page

Managing Editor

at Technology Networks

As managing editor, Laura works with the editorial director to create, inform and maintain the overall editorial strategy for Technology Networks. She oversees the in-house editorial team and works directly with commissioned writers to produce content across the publication’s communities. After obtaining a first-class honors degree in biology, Laura worked as a quality assurance technologist before joining the Wellcome Sanger Institute and undertaking an additional qualification in clinical chemistry. In 2015, she left to pursue pharmaceutical and editorial-based roles, before joining Technology Networks in 2017.

Education

University of Kent

Nottingham Trent University

Writtle University College

Chartered Institute of Editing and Proofreading

Accreditations

Biology, BSc (Hons) recognised by The University of Kent

Areas of Expertise

Drug Screening Strategies

Pharmaceutical Development

Molecular & Cellular Biology

Got a Question for Laura Elizabeth Lansdowne?

Get in touch using the contact form linked here and we’ll get back to you shortly

Published Content

Total: 409

Detecting Residual Cancer Using Whole-Genome Sequencing and Artificial Intelligence content piece image

Industry Insight

Detecting Residual Cancer Using Whole-Genome Sequencing and Artificial Intelligence

When a tumor is surgically removed, small amounts of residual cancer can remain at a level that is undetectable with current imaging or blood-based approaches. In this interview, Technology Networks spoke with Asaf Zviran, co-founder and CEO of C2i Genomics to find out more about the company’s C2-Intelligence Platform for the detection of trace amounts of cancer.

COVID-19: Therapeutics, Preventives and Industry Perspectives content piece image

Industry Insight

COVID-19: Therapeutics, Preventives and Industry Perspectives

Technology Networks had the pleasure of speaking with Ki-Sung Kwon, head of the R&D unit at Celltrion to learn more about therapeutic versus preventive strategies against COVID-19 and the company's monoclonal antibody-based therapeutic – CT-P59 – that is currently being developed against COVID-19.

Animal-Free Methods for Drug Safety Testing content piece image

Industry Insight

Animal-Free Methods for Drug Safety Testing

Animal-free testing methods are being increasingly explored and implemented as an alternative to animal models, in efforts to provide a more accurate prediction of a drug candidate’s efficacy and safety. InSphero recently hosted a virtual roundtable discussion on the topic of animal-free testing. Technology Networks had the pleasure of speaking with Armin Wolf, chief scientific officer at InSphero, to learn more about the topics discussed.

Non-Invasive Biomarker Can Track and Verify Senolytic Drug Efficacy content piece image

Non-Invasive Biomarker Can Track and Verify Senolytic Drug Efficacy

In a new study published in Cell Metabolism, scientists share their discovery of a novel, non-invasive biomarker test that can be utilized to measure and track the performance of senolytic drugs.

Microphysiological Systems content piece image

Microphysiological Systems

Microphysiological systems (MPS) are two- or three-dimensional cellular platforms that are designed to recapitulate the physiology and function of the human body in vitro.

Opinionated Science Episode 24: Mayan Bones, Boozy Brains and Baboon Logic content piece image

Opinionated Science Episode 24: Mayan Bones, Boozy Brains and Baboon Logic

In this episode, the TN team review what happens in the brain when we drink alcohol, find out how to use baboons and grapes to make discoveries about logic processing and unearth the rise-and-fall life story of an ancient Mayan.

The Development of Natural Killer Cells for Solid Tumor Treatment content piece image

Industry Insight

The Development of Natural Killer Cells for Solid Tumor Treatment

We interviewed Jan Davidson MD., PhD., the newly appointed chief medical officer at Wugen to learn more about the company's agreement with Washington University to further their Memory NK Cell program.

Behavioral Effects of Alcohol May Be Caused by Breakdown Products Produced in the Brain content piece image

Behavioral Effects of Alcohol May Be Caused by Breakdown Products Produced in the Brain

Researchers have demonstrated that alcohol metabolism can occur in the mouse brain, due to the presence of the enzyme aldehyde dehydrogenase 2 (ALDH2). They also demonstrated that expression of ALDH2 in the mouse cerebellum mediates behavioral effects related to alcohol intoxication. The paper was published in Nature Metabolism.

Improving Drug Discovery With Organoid-Based “Phase 0” Testing content piece image

Improving Drug Discovery With Organoid-Based “Phase 0” Testing

Technology Networks recently had the pleasure of speaking with Soumita Das, associate professor at the University of California San Diego, to learn more about her work with organoids and some of the research activities at the HUMANOID™ Center of Research Excellence.

Exploring Human Biology and Disease With Organoid Models content piece image

Exploring Human Biology and Disease With Organoid Models

Advances in cell culture techniques and stem cell technology have enabled the generation of organoids – three-dimensional aggregations of cells capable of recapitulating the structure and physiology of human organs in extraordinary detail. Technology Networks recently interviewed Soumita Das, associate professor at the University of California San Diego, to learn about the organoid models her team is developing.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter